Seeking Alpha

Somaxon Pharmaceuticals (SOMX) jumps in post-trade after saying it had a productive meeting with...

Somaxon Pharmaceuticals (SOMX) jumps in post-trade after saying it had a productive meeting with the FDA relating to the over-the-counter development program for its insomnia drug Silenor, developed jointly with Procter & Gamble (PG). SOMX +22.5% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs